Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Montserrat, L. (Lorenzo) | - |
dc.creator | Lopez-Salazar, M.B. (María Begoña) | - |
dc.creator | Gonzalez, A. (Arantxa) | - |
dc.creator | Hermida, M. (Manuel) | - |
dc.creator | Fernandez, X. (Xusto) | - |
dc.creator | Ortiz, M. (Martin) | - |
dc.creator | Barriales-Villa, R. (Roberto) | - |
dc.creator | Castro-Beiras, A. (Alfonso) | - |
dc.creator | Diez-Martinez, J. (Javier) | - |
dc.date.accessioned | 2012-04-30T10:12:32Z | - |
dc.date.available | 2012-04-30T10:12:32Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Monserrat L, Lopez B, Gonzalez A, Hermida M, Fernandez X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011 Jan;32(2):177-183. | es_ES |
dc.identifier.issn | 1522-9645 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21817 | - |
dc.description.abstract | Abstract AIMS: Cardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: The study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocardiogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the Spirito's LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls, patients with HCM exhibited higher (P < 0.001) plasma CT-1 levels. Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients. In addition, the levels of CT-1 were higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness <30 mm). CONCLUSIONS: These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Hypertrophic cardiomyopathy | es_ES |
dc.subject | Cardiotrophin | es_ES |
dc.subject | Hypertrophy | es_ES |
dc.title | Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://bit.ly/IJOn6X | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.